Thus, salsalate—a nonsteroidal anti-inflammatory drug (NSAID) approved by the FDA to treat arthritis and other conditions that cause swelling—has been shown to inhibit acetyltransferase p300-induced tau acetylation and improve tau-mediated behavioral impairments and neurodegeneration in an frontotemporal dementia (FTD) mouse model [34]. The gene discussed is MAPT; the disease is Arthritis.